News
Veru's enobosarm is designed to be used in combination with GLP-1 agonist-based obesity drugs – such as Novo Nordisk's blockbuster Wegovy (semaglutide) – to reduce the loss of lean muscle mass ...
Wegovy versus Ozempic for weight loss — it’s the age-old question. Okay, not that old. But it’s a common question amid the rising popularity of these weight loss drugs. Wegovy and Ozempic ...
The pharmaceutical company that makes the weight-loss drug Wegovy and the diabetes medication Ozempic secured a court victory that limits compounding pharmacies from selling versions of those ...
LONDON, April 24 (Reuters) - Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk (NOVOb.CO), opens new tab has raised its annual sales guidance several times a year.
LONDON (Reuters) - Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several times a year. But recent weak U.S. prescription ...
Generic versions of Ozempic, Wegovy, and Mounjaro flooded into the market via med spas and online pharmacies. In February of this year, the FDA announced that the shortage had been resolved—and ...
The South Korean office of the Danish pharmaceutical company Novo Nordisk recently requested the local authorities to permit the use of its anti-obesity medication Wegovy for children aged 12 and ...
LONDON (Reuters) - Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several times a year. But recent weak U.S. prescription data is ...
A federal judge in Texas late Thursday rejected a bid by compounding pharmacies to keep making copies of Ozempic and Wegovy while a legal challenge over the shortage of those drugs unfolds.
The United States Food and Drug Administration (FDA) has stopped the sale of copycat versions of Ozempic and Wegovy, the Type 2 diabetes drugs used for weight loss. In 2022, the FDA announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results